Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
The drug will be available in 600 hospitals and 105 DTPs
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Tislelizumab is now approved for seven indications in China
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Subscribe To Our Newsletter & Stay Updated
